Oncorus, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-04-01
- Employees
- 64
- Market Cap
- -
- Website
- http://www.oncorus.com
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid TumorCancerNon-melanoma Skin CancerLiver MetastasesSquamous Cell Carcinoma of Head and NeckColorectal CarcinomaBreast CancerMelanomaSolid TumorTriple Negative Breast Cancer
- Interventions
- Biological: ONCR-177Biological: pembrolizumab
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Oncorus, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT04348916
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Emory University, Atlanta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath